For R&D, formulation, and regulatory professionals evaluating their safety testing programs, the shift toward in vitro methods is no longer a trend. It’s the established standard.
1. Regulatory frameworks have already moved in the EU and across the U.S.
Animal testing restrictions for cosmetics are not pending legislation. The European Union banned animal testing for cosmetics ingredients and finished products years ago. In the U.S., more than a dozen states, including California, New York, New Jersey, Illinois, Maryland, Oregon, Virginia, Hawaii, and Washington, have enacted prohibitions on the sale of animal-tested cosmetics. For compliance and regulatory teams managing multi-market product portfolios, in vitro testing is not a future-state consideration. It is the current compliance requirement.
2. The translational accuracy argument has been settled in favor of human tissue models.
The fundamental problem with animal-based testing was always the translational gap: animal biology does not reliably predict human response. In vitro testing using reconstructed human cell and tissue constructs resolved this. Because the test substrate directly mirrors human biology, the resulting safety data has greater specificity for human exposure and greater defensibility in a regulatory submission context. The scientific community and regulatory bodies have aligned on this. The question is no longer whether in vitro methods are adequate substitutes, but which methods apply to which endpoints.
3. Faster, reproducible results have made in vitro testing the practical choice for formulation teams.
In vitro testing generates results faster than traditional animal model studies and with a higher degree of reproducibility across testing events. For R&D and formulation teams, this means safety data can be integrated earlier in the development cycle, before reformulation decisions, not after. The operational advantage of rapid, reproducible safety feedback has made in vitro testing the practical default for competitive product development timelines, independent of any regulatory mandate.
4. EpiDerm™ delivers human-relevant skin irritation and corrosion classification.
EpiDerm™ is a reconstructed human epidermis model that measures cellular viability following exposure to controlled substances and classifies products and ingredients across a defined spectrum from non-irritating to severely corrosive. It aligns with internationally recognized regulatory standards and has been accepted by regulatory authorities as a validated method for assessing skin safety. For formulators working with actives, preservative systems, or novel ingredient combinations, EpiDerm™ produces human tissue-based safety data that animal proxies have never been well positioned to provide.
5. EpiOcular™ has become the standard for ocular safety assessment.
EpiOcular™ is a reconstructed human corneal tissue model that assesses the irritation potential of cosmetic products and ingredients at the ocular level. It measures tissue response following exposure, classifies results against UN GHS standards, and generates the ocular safety data required for complete product safety dossiers. Where eye irritation testing was once synonymous with animal models, EpiOcular™ has replaced that approach with a validated, human-relevant method that regulatory authorities recognize and the industry has adopted broadly.
Get Started with In Vitro Toxicology Cosmetic Testing
CPT℠ Labs offers EpiDerm™ and EpiOcular™ in vitro toxicology testing for cosmetics manufacturers, formulators, and product development teams. Start your quote today!